Jazz Pharmaceuticals PLC (JAZZ)
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on identifying, developing, and commercializing prescription medicines in the United States, Europe, and other international markets. Its commercial portfolio includes therapies for narcolepsy and idiopathic hypersomnia, epilepsy and seizure disorders, certain cancers, and severe veno-occlusive disease. Key marketed products include Xywav, Epidiolex, Rylaze, Enrylaze, Zepzelca, Ziihera, Modeyso, and Defitelio. The company also advances several pipeline programs, including Zanidatamab, Dordaviprone, Vyxeos, JZP3507, JZP815, JZP898, and JZP047, across a range of oncology and neurological indications. Founded in 2003, Jazz Pharmaceuticals plc is headquartered in Dublin, Ireland, and maintains licensing and collaboration agreements with several biotechnology and pharmaceutical partners.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-JAZZ
|
$304.81
|
22.5% Upside
|
Undervalued
|
$263.10
|
5.7% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
528.3x
|
3.4x
|
3.5x
|
15.294 B
|
18.103 B
|
26.2%
|
96.9%
|
8.5
|
—
|
4,310.8%
|
